Archer Materials Limited · ASX:AXE

Archer Materials — H1 FY2026 Earnings Presentation

11 slides from Archer Materials's earnings presentation, Mar 4, 2026

  1. Slide 1: 1H FY26 Update - Presentation (ASX Announcement)

    Archer Materials Archer Materials Limited (ACN: 123 993 233) Corporate Lot Fourteen, Frome Road, Adelaide SA 5000 www.archerx.com.au ASX Announcement (ASX: AXE) 4 March 2026 1H FY26 Update - Presentation Archer Materials Limited (“Archer”, the “Company”, “ASX: AXE”) is pleased to enclose a copy of t

  2. Slide 2: 1H FY26 results

    For personal use only 1H FY26 results Dr Simon Ruffell, Chief Executive Officer 4 March 2026

  3. Slide 3: Archer at a Glance

    Archer at a Glance Archer Materials (ASX: AXE) is the only ASX-listed quantum technology company. We are For personal use only developing IP for use in quantum computing, sensing and medical diagnostics. Technology roadmap of IP in medical, Development partnerships with world-class R&D quantum sensi

  4. Slide 4: Quantum Machine Learning fraud detection project

    NEW PROJECT Quantum Machine Learning QML fraud detection project reinforces Archer’s strategy to commercialise For personal use only near-term quantum  Archer has partnered with CSIRO to develop Quantum Machine applications with global Learning (QML) models for fraud detection impact.  Initial out

  5. Slide 5: 1H FY26 Overview

    For personal use only 1H FY26 Overview

  6. Slide 6: 1H FY26 Highlights: Quantum

    QUANTUM 1H FY26 Highlights Towards qubit demo, sensing applications, and For personal use only  Overall  Advanced with technical derisking software  Technology IP portfolio broadening  12CQ carbon-based qubit material platform  Achieved fundamental readout milestones for our carbon qubits  Ent

  7. Slide 7: 1H FY26 Highlights: Biochip

    BIOCHIP 1H FY26 Highlights Moving toward biochip beta prototype demonstration in 2026 For personal use only  Overall  Technical, supply-chain, manufacturability derisking.  Early system prototype - basis for partner meetings and pre- clinical testing.  Improved route to commercialisation  Compl

  8. Slide 8: Outlook

    For personal use only Outlook

  9. Slide 9: 2026 Key Milestones

    2026 Key Milestones ‣ Lab demonstrator/alpha prototype of blood potassium delivered in early 2026. ‣ Blood potassium beta prototype sensor in For personal use only Calendar years to 2027 2026 for use in trials Early demo of next gen biochip Biochip lab Biochip Biochip clinical ‣ End of 2026 begin cl

  10. Slide 10: Disclaimer

    Disclaimer The material contained in this document is a presentation of general information about the activities of Archer Materials Ltd and its related bodies For personal use only corporate (together the “Archer Group”), current as at the date of this presentation. It is provided in summary and do

  11. Slide 11: Thank you

    Thank you For personal use only Sydney Adelaide Subscribe to ASX Code: AXE our newsletter Level 2, 477 Pitt St Lot Fourteen, Frome Rd Sydney NSW 2000 Adelaide SA 5000 Archer Materials Limited ABN 64 123 993 233 archerx.com.au

Archer Materials — H1 FY2026 Earnings Presentation on 6ix